Search Results
Feb 10, 2026, 09:00 ET AsymBio crée des plates-formes technologiques intégrées couvrant l'ensemble du cycle de développement biopharmaceutique
fiable de thérapies innovantes.À propos d'AsymBioAsymBio se concentre exclusivement sur les services CDMO biopharmaceutiques. L'entreprise propose des services CDMO complets, du développement précoce à la fabrication à l'échelle commerciale, en passant par les essais cliniques et la
More news about: AsymBio
Feb 10, 2026, 09:00 ET AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle
AsymBioAsymBio, a subsidiary of Asymchem Group, focuses exclusively on biopharmaceutical CDMO services. With more than 25 years of experience and global operations, the company delivers one-stop CDMO services from early-stage and process development to clinical, toxicology, and commercial-scale
More news about: AsymBio
Feb 10, 2026, 08:07 ET On Site: "2026 China Forum on Source Innovation in New Drug Discovery" Concludes Successfully
BiotechChina's ecosystem for innovative drugs has taken shape and already demonstrates significant achievements. Strengths are particularly notable in CRO/CDMO services and early-stage R&D, with active outbound licensing and collaboration. However, several key gaps remain. Payment and reimbursement systems
More news about: Sanyou Bio
Feb 09, 2026, 08:00 ET BioDlink Recognized by Client for Enabling the World's First Dual-Payload ADC to Enter Clinical Trials
Research Ethics Committee (HREC) on March 21, 2025 followed by clinical trial authorization in China on April 15, 2025.As Kanghong Pharmaceutical's CDMO partner, BioDlink supported the program across the full development lifecycle, including process development, analytical method development and validation,
More news about: BioDlink Biopharm Co., Ltd.
Feb 06, 2026, 08:00 ET Samsung Biologics leads climate transparency with independent validation of Product Carbon Footprint system
Feb. 6, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that its product carbon footprint (PCF) system has been validated by Det Norske Veritas (DNV), an independent third-party assurance provider,
More news about: Samsung Biologics
Feb 05, 2026, 11:44 ET FIS completa con éxito la emisión de bonos por valor de 770 millones de euros
la producción de Ingredientes Farmacéuticos Activos (API) para la industria farmacéutica global, destacando como referente internacional en el sector CDMO (Organización de Desarrollo y Fabricación por Contrato). FIS opera a través de tres plantas en Italia (Montecchio Maggiore, Termoli y Lonigo), oficinas
More news about: FIS
Feb 05, 2026, 11:37 ET FIS CONCLUT AVEC SUCCÈS L'ÉMISSION D'OBLIGATIONS POUR UN MONTANT DE 770 MILLIONS D'EUROS
d'ingrédients pharmaceutiques actifs (API) pour l'industrie pharmaceutique mondiale, se distinguant comme une référence internationale dans le secteur des CDMO (Contract Development and Manufacturing Organization). FIS opère à travers trois usines en Italie (Montecchio Maggiore, Termoli et Lonigo), des bureaux
More news about: FIS
Feb 05, 2026, 10:03 ET FIS SCHLIESST ANLEIHEEMISSION IN HÖHE VON 770 MILLIONEN EURO ERFOLGREICH AB
der Entwicklung und Produktion von pharmazeutischen Wirkstoffen (APIs) für die globale Pharmaindustrie und gilt als internationale Referenz im Bereich CDMO (Contract Development and Manufacturing Organization). FIS betreibt drei Werke in Italien (Montecchio Maggiore, Termoli und Lonigo), Handelsbüros in
More news about: FIS
Feb 05, 2026, 09:09 ET FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE
and production of Active Pharmaceutical Ingredients (APIs) for the global pharmaceutical industry, standing out as an international benchmark in the CDMO (Contract Development and Manufacturing Organization) sector. FIS operates through three plants in Italy (Montecchio Maggiore, Termoli and Lonigo),
More news about: FIS
Feb 05, 2026, 09:04 ET FIS SUCCESSFULLY COMPLETES €770 MILLION BOND ISSUANCE
and production of Active Pharmaceutical Ingredients (APIs) for the global pharmaceutical industry, standing out as an international benchmark in the CDMO (Contract Development and Manufacturing Organization) sector. FIS operates through three plants in Italy (Montecchio Maggiore, Termoli and Lonigo),
More news about: FIS
Feb 05, 2026, 04:00 ET BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration
Biotechnologies, leading a 5,000+ person global CDMO across Denmark, UK, US, and Japan. He brings 30+ years' experience in biomanufacturing.Lucy Foley, CEO, eXmoor- Lucy is CEO of eXmoor Pharma, a UK-based cell and gene therapy CDMO. She is Vice Chair of the BIA Manufacturing Advisory
More news about: BioPhorum
Feb 04, 2026, 08:00 ET Stevenson Search Partners Announces Amelia Tyagi as Inaugural Advisory Board Member
executive search and total talent solutions advisor servicing the global biotechnology, pharmaceutical, medical technology, health technology and CRO/CDMO sectors, with offices in the U.S. and the U.K. Dedicated to finding executive talent who will drive innovation across the life sciences industry, Stevenson's
More news about: Stevenson Search Partners
Feb 03, 2026, 08:00 ET BioDlink Modernizes Quality Management with Successful Go-Live of Veeva QMS
Development and Manufacturing Organization (CDMO) specializing in biologics, is committed to being the trusted partner of choice for biopharmaceutical innovators worldwide. Leveraging our advanced one-base integrated platform, BioDlink delivers end-to-end CDMO services for protein-based therapeutics (such
More news about: BioDlink Biopharm Co., Ltd.
Feb 03, 2026, 08:00 ET CEPI and Samsung Biologics collaborate to strengthen outbreak-ready vaccine production and global access
for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced a partnership to strengthen vaccine manufacturing preparedness for future epidemic and pandemic threats. The collaboration will see
More news about: Samsung Biologics
Feb 03, 2026, 07:06 ET Piramal Pharma Solutions présente des capacités de comprimé en gélule
3 février 2026 /PRNewswire/ -- Piramal Pharma Solutions est une organisation mondiale de développement et de fabrication sous contrat (CDMO) de premier plan qui fait partie de Piramal Pharma Ltd. (NSE : PPLPHARMA | BSE : 543635), a le plaisir d'annoncer le succès du développement,
More news about: Piramal Pharma Solutions
Feb 03, 2026, 04:39 ET Piramal Pharma Solutions introduce la tecnologia tablet-in-capsule
Solutions, un'organizzazione leader a livello mondiale nello sviluppo e nella produzione a contratto (Contract Development and Manufacturing Organization, CDMO) e parte di Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), è lieta di annunciare il successo dello sviluppo, dell'ampliamento e della commercializzazione
More news about: Piramal Pharma Solutions
Feb 02, 2026, 14:41 ET Piramal Pharma Solutions presenta capacidades de comprimido en cápsula
2 de febrero de 2026 /PRNewswire/ -- Piramal Pharma Solutions, organización líder mundial en desarrollo y fabricación por contrato (CDMO) y parte de Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), se complace en anunciar el exitoso desarrollo, escalado y comercialización de un sistema
More news about: Piramal Pharma Solutions
Feb 02, 2026, 13:10 ET Piramal Pharma Solutions stellt seine Fähigkeiten im Bereich Tablette-in-Kapsel vor
Piramal Pharma Solutions, ein weltweit führendes Auftragsentwicklungs- und Produktionsunternehmen (Contract Development and Manufacturing Organization, CDMO) und Teil von Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), freut sich, die erfolgreiche Entwicklung, Skalierung und Vermarktung eines Tablette-in-Kapsel-Arzneimittelabgabesystems
More news about: Piramal Pharma Solutions
Feb 02, 2026, 11:07 ET Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Feb. 2, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), is pleased to announce the successful development, scale-up, and commercialization
More news about: Piramal Pharma Solutions
Feb 02, 2026, 11:00 ET Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Feb. 2, 2026 /PRNewswire/ -- Piramal Pharma Solutions, a leading global Contract Development and Manufacturing Organization (CDMO) and part of Piramal Pharma Ltd. (NSE: PPLPHARMA | BSE: 543635), is pleased to announce the successful development, scale-up, and commercialization
More news about: Piramal Pharma Solutions
Jan 31, 2026, 07:57 ET Piramal Pharma Limited annuncia i risultati del terzo trimestre e dei primi nove mesi dell'anno fiscale 2026
(4) %CDMO1.166
More news about: Piramal Pharma Limited
Jan 30, 2026, 09:30 ET I Peace Announces Successful Generation of Human iPS Cells from NKT Cells and Commences Their Availability
PALO ALTO, Calif., Jan. 30, 2026 /PRNewswire/ -- Leading GMP cell therapy CDMO I Peace, Inc. (https://ipeace.com/en/), specializing in induced pluripotent stem
More news about: I Peace, Inc.
Jan 30, 2026, 03:07 ET Piramal Pharma Limited gibt Ergebnisse für das dritte Quartal und die ersten neun Monate des Geschäftsjahres 2026 bekannt
(4) % CDMO1,166
More news about: Piramal Pharma Limited
Jan 29, 2026, 13:24 ET Piramal Pharma Limited anuncia resultados del tercer trimestre y nueve meses del año fiscal 2026
(4) % CDMO1.166
More news about: Piramal Pharma Limited
Jan 29, 2026, 13:17 ET Piramal Pharma Limited annonce ses résultats pour le troisième trimestre et les neuf premiers mois de l'exercice 2026
(4) % CDMO1 166
More news about: Piramal Pharma Limited